This cost-effectiveness study found that initiation of population-wide screening for CKD followed by treatment with conventional CKD therapy combined with SGLT2 inhibitors at age 55 years was cost-effective for US adults. This evidence concerns the gene SLC5A2 and chronic kidney disease.